Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genpact's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genpact's regulatory disclosures and financial reporting.
A holder of common stock of G has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 16,016 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 01/13/2026. The aggregate market value of the shares listed for sale is $747,122.38, compared with 172,414,423 shares outstanding of the same class.
The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026, with the consideration described as not applicable. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Genpact Limited reported that its SVP and Chief Legal Officer, Sydney Schaub, received an award of 63,357 common shares in the form of unvested restricted share units on 01/06/2026 at a grant price of $0 per share. Each RSU represents the right to receive one Genpact common share upon vesting. One-third of the shares underlying this RSU award will vest on each of December 8, 2026, December 8, 2027 and December 8, 2028, as long as Schaub continues in service through each vesting date. Following this grant, Schaub beneficially owned 63,357 common shares directly.
Genpact Limited reported an insider equity award to its President and CEO, who is also a director. On December 17, 2025, the executive received 125,130 restricted share units (RSUs) of Genpact common shares at a price of $0 per share, granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU converts into one common share when it vests.
One-third of the shares underlying this RSU award will vest on each of December 17, 2026, December 17, 2027 and December 17, 2028, contingent on the executive’s continued service through each vesting date. After this transaction, the executive beneficially owns 420,376 Genpact common shares directly.
Genpact LTD disclosed an insider ownership report for one of its senior executives. The filing relates to Sydney Schaub, who serves as SVP and Chief Legal Officer, with an event date of 12/08/2025.
According to the filing, no Genpact securities are beneficially owned, as noted in the explanation of responses. The form is filed for a single reporting person and is signed by Thomas D. Scholtes as attorney-in-fact for Sydney Schaub under a referenced power of attorney (Exhibit 24.1).
Genpact Limited announced that its subsidiaries Genpact UK Finco plc and Genpact USA, Inc. completed a public Notes Offering of $350 million aggregate principal amount of 4.950% Senior Notes due 2030. The notes are senior unsecured obligations of the co-issuers and are guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes bear interest at 4.950% per year, payable semi-annually on May 18 and November 18, starting May 18, 2026, and mature on November 18, 2030.
Genpact intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming its existing 1.750% senior notes due 2026. The new notes include customary covenants and a change of control repurchase right at 101% of principal plus accrued interest. Genpact UK also agreed to fully and unconditionally guarantee the 2026 and 6.000% 2029 notes and became a guarantor under the company’s second amended and restated credit agreement, further aligning guarantees across its debt structure.
Genpact Ltd (G) reported that its Chief Financial Officer filed a Form 4 disclosing an open-market sale of company stock. On 11/14/2025, the CFO sold 13,365 common shares of Genpact at a weighted average price of $44.84 per share, with individual sale prices ranging from $44.81 to $44.89. Following this transaction, the reporting person beneficially owns 148,026 Genpact common shares. This total includes 1,358 shares held under the Genpact Employee Stock Purchase Plan, of which 169 shares were acquired under the plan since a prior report filed on March 13, 2025.
Genpact UK Finco plc and Genpact USA, Inc. priced a $350,000,000 offering of 4.950% Senior Notes due 2030, fully and unconditionally guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes mature on November 18, 2030 and pay interest semi-annually on May 18 and November 18, starting May 18, 2026.
The notes were offered at 99.593% with a 0.400% underwriting discount, resulting in proceeds before expenses of $347,175,500; Genpact estimates net proceeds of approximately $345.4 million. The company intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming the 1.750% Senior Notes due 2026, of which approximately $350 million is outstanding, at or prior to their April 10, 2026 maturity.
The notes are senior unsecured obligations with optional redemption at a make‑whole premium before October 18, 2030 and at par thereafter, and include a change of control repurchase at 101% of principal. Genpact plans to apply to list the notes on The International Stock Exchange; there is currently no public market.
Form 144 filing: A holder notified intent to sell up to 13,365 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/14/2025. The filing lists an aggregate market value of $599,314.67 for the planned sale.
The shares were acquired as restricted stock from the issuer on 08/02/2022. As context, 172,414,423 shares were outstanding at the time referenced.
Genpact (G) reported insider transactions by its SVP & Chief Legal Officer. On 11/11/2025, the officer sold 1,039 common shares at $44.02. On 11/12/2025 and 11/13/2025, the officer exercised employee stock options at $27.7 for 4,351 and 45,703 shares, respectively, and sold the corresponding shares at $45.74. Following these transactions, the officer directly beneficially owned 50,569 common shares. The reported option grant was scheduled to expire on 01/09/2029 and vested 50% on January 10, 2022 and 50% on January 10, 2024.
Genpact Ltd (G) — Form 4 insider transaction: Senior Vice President Sameer Dewan reported a sale of 26,531 common shares on 11/11/2025, coded “S” for sale. The weighted average price was $44.7, with disclosed trade prices ranging from $44.70 to $44.7305.
Following the transaction, Dewan beneficially owns 62,617 shares, held directly.